表紙
市場調査レポート

Immuron Limitedの製品パイプライン分析

Immuron Limited - Product Pipeline Review - 2015

発行 Global Markets Direct 商品コード 253821
出版日 ページ情報 英文 26 Pages
即納可能
価格
本日の銀行送金レート: 1USD=102.12円で換算しております。
Back to Top
Immuron Limitedの製品パイプライン分析 Immuron Limited - Product Pipeline Review - 2015
出版日: 2015年10月30日 ページ情報: 英文 26 Pages
概要

Immuron Limitedは、ヒト用ポリクローナル抗体製品を開発するバイオ医薬品企業です。

当レポートでは、Immuron Limitedにおける治療薬開発パイプラインの現況と各開発段階の比較分析、薬剤標的、作用機序、投与経路、分子タイプ別の治療薬の評価、最新の企業ニュースや発表、後期段階および中止されたプロジェクトに関する情報などを提供しています。

Immuron Limitedの基本情報

Immuron Limitedの概要

  • 主要情報
  • 企業情報

Immuron Limited:R&Dの概要

  • 主な治療範囲

Immuron Limited:パイプラインのレビュー

  • 開発段階別のパイプライン製品
  • 単剤製品

Immuron Limited:パイプライン製品の概況

  • 治験段階にあるパイプライン製品
    • 第II相にある製品/併用療法モダリティ
  • 初期段階にあるパイプライン製品
    • 前臨床段階にある製品/併用療法モダリティ
    • 創薬中の製品/併用療法モダリティ

Immuron Limited:薬剤プロファイル

  • IMM-124E
  • IMM-243
  • IMM-160
  • IMM-529
  • IMM-252

Immuron Limited:パイプライン分析

  • 投与経路別
  • 分子タイプ別

Immuron Limited:最近のパイプライン動向

Immuron Limited:休止中のプロジェクト

Immuron Limited:本社と子会社の所在地

付録

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GMDHC07721CDB

Summary

Global Markets Direct's, 'Immuron Limited - Product Pipeline Review - 2015', provides an overview of the Immuron Limited's pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Immuron Limited's, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides brief overview of Immuron Limited including business description, key information and facts, and its locations and subsidiaries
  • The report reviews current pipeline of Immuron Limited's human therapeutic division and enlists all their major and minor projects
  • The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones
  • Special feature on out-licensed and partnered product portfolio
  • The report summarizes all the dormant and discontinued pipeline projects
  • Latest company statement
  • Latest news and deals relating to the Immuron Limited's pipeline products

Reasons to buy

  • Evaluate Immuron Limited's strategic position with total access to detailed information on its product pipeline
  • Assess the growth potential of Immuron Limited in its therapy areas of focus
  • Identify new drug targets and therapeutic classes in the Immuron Limited's R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
  • Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
  • Develop strategic initiatives by understanding the focus areas of Immuron Limited and exploit collaboration and partnership opportunities
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Plan mergers and acquisitions effectively by identifying the most promising pipeline of Immuron Limited
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Explore the dormant and discontinued projects of Immuron Limited and identify potential opportunities in those areas
  • Avoid Intellectual Property Rights related issues

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Immuron Limited Snapshot
    • Immuron Limited Overview
    • Key Information
    • Key Facts
  • Immuron Limited - Research and Development Overview
    • Key Therapeutic Areas
  • Immuron Limited - Pipeline Review
    • Pipeline Products by Stage of Development
    • Pipeline Products - Monotherapy
  • Immuron Limited - Pipeline Products Glance
    • Immuron Limited - Clinical Stage Pipeline Products
      • Phase II Products/Combination Treatment Modalities
    • Immuron Limited - Early Stage Pipeline Products
      • Preclinical Products/Combination Treatment Modalities
      • Discovery Products/Combination Treatment Modalities
  • Immuron Limited - Drug Profiles
    • IMM-124E
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Antibody for Colitis
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • IMM-160
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • IMM-363
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • IMM-529
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • IMM-252
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Immuron Limited - Pipeline Analysis
    • Immuron Limited - Pipeline Products by Route of Administration
    • Immuron Limited - Pipeline Products by Molecule Type
  • Immuron Limited - Recent Pipeline Updates
  • Immuron Limited - Dormant Projects
  • Immuron Limited - Locations And Subsidiaries
    • Head Office
    • Other Locations & Subsidiaries
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Immuron Limited, Key Information
  • Immuron Limited, Key Facts
  • Immuron Limited - Pipeline by Indication, 2015
  • Immuron Limited - Pipeline by Stage of Development, 2015
  • Immuron Limited - Monotherapy Products in Pipeline, 2015
  • Immuron Limited - Phase II, 2015
  • Immuron Limited - Preclinical, 2015
  • Immuron Limited - Discovery, 2015
  • Immuron Limited - Pipeline by Route of Administration, 2015
  • Immuron Limited - Pipeline by Molecule Type, 2015
  • Immuron Limited - Recent Pipeline Updates, 2015
  • Immuron Limited - Dormant Developmental Projects,2015
  • Immuron Limited, Other Locations

List of Figures

  • Immuron Limited - Pipeline by Top 10 Indication, 2015
  • Immuron Limited - Pipeline by Stage of Development, 2015
  • Immuron Limited - Monotherapy Products in Pipeline, 2015
  • Immuron Limited - Pipeline by Top 10 Route of Administration, 2015
  • Immuron Limited - Pipeline by Top 10 Molecule Type, 2015
Back to Top